ALLK Sep 2022 7.500 call
| Previous close | 0.3900 |
| Open | 0.4000 |
| Bid | 0.3500 |
| Ask | 0.5000 |
| Strike | 7.50 |
| Expiry date | 2022-09-16 |
| Day's range | 0.4000 - 0.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.76k |
- GlobeNewswire
Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results
SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2022. Recent Allakos Events Submitted End-of-Phase 2 briefing package to FDA to discuss Phase 2 KRYPTOS data and development pathway of lirentelimab in patients with eosinophil
- GlobeNewswire
Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors
SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the appointment of Amy L. Ladd, M.D., orthopaedic surgeon and professor at Stanford University, to the Allakos board of directors. “We are very pleased to have such an accomplished physician as Dr. Ladd join our board. Her extensive medical background and expert
- Simply Wall St.
Companies Like Allakos (NASDAQ:ALLK) Could Be Quite Risky
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
